131292-83-6

Basic information

• Product Name: Methanesulfonic acid, trifluoro-, [bis(phenylmethoxy)phosphinyl]methyl ester
• CAS NO: 131292-83-6
• Molecular Formula: C16H16F3O6PS
• Molecular Weight: 424.334
• Mol File: 131292-83-6.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Methanesulfonic acid, trifluoro-, [bis(phenylmethoxy)phosphinyl]methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Methanesulfonic acid, trifluoro-, [bis(phenylmethoxy)phosphinyl]methyl ester(131292-83-6)
• EPA Substance Registry System: Methanesulfonic acid, trifluoro-, [bis(phenylmethoxy)phosphinyl]methyl ester(131292-83-6)

Safety Data

• Hazardous Substances Data: 131292-83-6(Hazardous Substances Data)

Upstream product

• 421-83-0 trifluoromethane sulfonyl chloride 
• 114790-35-1 dibenzyl hydroxymethylphosphonate 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 17176-77-1 Dibenzyl phosphite 
• 538-60-3 dibenzyl hydrogen phosphite 

Downstream Products

• 622868-88-6 (2-hydroxy-ethoxymethyl)-phosphonic acid dibenzyl ester 
• 1326780-14-6 C₃₂H₄₆NO₉PSi 
• 1326780-13-5 C₃₂H₄₆NO₉PSi 
• 684285-96-9 C₃₅H₃₀FN₂O₈P 
• 259792-37-5 4,5,6-tri-O-benzyl-2,3-dideoxy-3-{[(dibenzyloxyphosphoryl)methyl]amino}-2-(trifluoroacetamido)-D-mannono-1,3-lactam 
• 259792-36-4 2-azido-4,5,6-tri-O-benzyl-2,3-dideoxy-3-{[(dibenzyloxyphosphoryl)methyl]amino}-D-mannono-1,3-lactam 
• 216772-31-5 2,3,4,5-tetra-O-benzyl-N-methyl-D-arabinonamide 
• 131292-85-8 Dibenzyl <<(2'R,3'S,4'S)-3'-Acetamido-4'-(benzyloxy)-2'-<(1''S,2''R)-1'',2'',3''-tris(benzyloxy)propyl>-pyrrolidin-1'-yl>methyl>phosphonate 

Relevant articles and documents

Rational design and synthesis of novel nucleotide anti-Giardia agents

Design and synthesis of a novel nucleotide anti-Giardia agent that is micromolar inhibitor of Giardia trophozoite growth in culture is described.

Synthesis and screening of novel inositol phosphonate derivatives for anticancer functions in vitro

Phosphonates have been frequently used as suitable isosteric and isoelectronic replacements for biologically important phosphates in the development of drugs or drug candidates because of their stability toward the action of phosphatases and other enzymes. In this paper, 12 mono-phosphonate inositol compounds were prepared with phosphonate instead of phosphate by two kinds of strategies, nucleophilic substitution and Arbuzov rearrangement, respectively. All compounds were evaluated in vitro for their activity against non-small cell lung cancer (NSCLC) cell line A549. Two compounds (3ac and 3bb) exhibited good antitumor activity at 10 μg/mL.

β-lactams from D-erythrose-derived imines: A convenient synthesis of 2,3-diamino-2,3-dideoxy-d-mannonic-acid derivatives

The D-manno-configured N-anisylated β-lactam 40, the β-lactam carboxylic acids 4 and 43, and the corresponding phosphonic-acid isosters 49 and 50 have been synthesized from D-glucose in 8-10 steps, respectively. None of these compounds exhibited a significant inhibitory activity in vitro against the sialidases of Vibrio cholerae, Salmonella typhimurium, Influenza A (N9), and Influenza B virus. Cycloaddition of the in situ generated imines derived from the D-erythroses 6, 16, and 17 with the ketene from mesyloxyacetyl chloride (20) gave the 2-mesyloxy-D-hexono-1,3-lactams 25, 27a/b, 28a/b/c, and 29 in 23, 69, 57, and 90% yield, respectively (Scheme 3). Transformation of 27a/b and 29 (> 85%) to the corresponding azides, followed by oxidative N-deprotection, gave 30a/b (45%) and 34 (80%). Subsequent alkylation of the ring N-atom in 31a with benzyl bromoacetate and dibenzyl (triflyloxymethyl)phosphonate 46 gave the carboxylate 41 (77%) and the phosphonate 47 (55%; Schemes 4 and 5). Hydrogenolysis of 41 gave the β- lactam amino acid 43, besides its hydrolysis product 44. Reductive N- acylation of the azido group in 41 (93%), followed by hydrogenolytic debenzylation, yielded the 2-trifluoroacetamido N-(carboxymethyl)-β-lactam 4 (56%). Similarly, 47 gave the 2-trifluoroacetamide 48 (89%), and hence, the 2-amino-N-(phosphonoylmethyl)-β-lactams 49 (40%) and 50, resulting from deacylation of 49 (14%). Aminolysis and carbamoylation of the protected β- lactams 31a and 35 led to the 2,3-diamino-2,3-dideoxy-D-mannonamides 51 and 53, respectively (Scheme 6).